384 related articles for article (PubMed ID: 23197490)
1. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
2. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
4. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer.
Kawazoe A; Shitara K; Fukuoka S; Kuboki Y; Bando H; Okamoto W; Kojima T; Fuse N; Yamanaka T; Doi T; Ohtsu A; Yoshino T
BMC Cancer; 2015 Apr; 15():258. PubMed ID: 25886136
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
Shiroiwa T; Motoo Y; Tsutani K
Mol Diagn Ther; 2010 Dec; 14(6):375-84. PubMed ID: 21275455
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
7. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
8. High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.
Guedes JG; Veiga I; Rocha P; Pinto P; Pinto C; Pinheiro M; Peixoto A; Fragoso M; Raimundo A; Ferreira P; Machado M; Sousa N; Lopes P; Araújo A; Macedo J; Alves F; Coutinho C; Henrique R; Santos LL; Teixeira MR
BMC Cancer; 2013 Apr; 13():169. PubMed ID: 23548132
[TBL] [Abstract][Full Text] [Related]
9.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications.
Italiano A; Hostein I; Soubeyran I; Fabas T; Benchimol D; Evrard S; Gugenheim J; Becouarn Y; Brunet R; Fonck M; François E; Saint-Paul MC; Pedeutour F
Ann Surg Oncol; 2010 May; 17(5):1429-34. PubMed ID: 20049644
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
12. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Mancl EE; Kolesar JM; Vermeulen LC
Am J Health Syst Pharm; 2009 Dec; 66(23):2105-12. PubMed ID: 19923311
[TBL] [Abstract][Full Text] [Related]
14. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
15. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
Frank M; Mittendorf T
Pharmacoeconomics; 2013 Mar; 31(3):215-28. PubMed ID: 23338963
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
17. Re: Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Hess LM; Carter G; Smolen L; Bowman L; von Hohnhorst P; Seagle C
J Natl Cancer Inst; 2014 Feb; 106(2):djt370. PubMed ID: 24381069
[No Abstract] [Full Text] [Related]
18. Mutation screening for KRAS and BRAF in metastatic colorectal cancer proves costly in relation to benefits.
Pharmacogenomics; 2013 Jan; 14(2):124. PubMed ID: 23447823
[No Abstract] [Full Text] [Related]
19. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
Westwood M; van Asselt T; Ramaekers B; Whiting P; Joore M; Armstrong N; Noake C; Ross J; Severens J; Kleijnen J
Health Technol Assess; 2014 Oct; 18(62):1-132. PubMed ID: 25314637
[TBL] [Abstract][Full Text] [Related]
20. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
Loupakis F; Ruzzo A; Cremolini C; Vincenzi B; Salvatore L; Santini D; Masi G; Stasi I; Canestrari E; Rulli E; Floriani I; Bencardino K; Galluccio N; Catalano V; Tonini G; Magnani M; Fontanini G; Basolo F; Falcone A; Graziano F
Br J Cancer; 2009 Aug; 101(4):715-21. PubMed ID: 19603018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]